Syremis Therapeutics Launches with $165M to Develop Best-in-Class Medicines for Mental Health Conditions
18.12.2025 14:00:00 CET | Business Wire | Press Release
Syremis Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health, today announced its launch with a $165 million financing. The Series A, co-led by Dexcel Pharma and Third Rock Ventures, with participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet will support the advancement of Syremis’ pipeline through clinical proof of concept.
Schizophrenia and other psychotic disorders remain among the most debilitating and underserved conditions worldwide, with more than 20 million people affected and facing considerable disability, elevated relapse rates, and reduced life expectancy. Despite decades of need, current treatments often fall short in both efficacy and tolerability.
Syremis’ lead program, ST-905, is a dual M1/M4 muscarinic agonist under development for schizophrenia and other neuropsychiatric conditions and is currently in Phase 1. The molecule’s differentiated potency and favorable pharmaceutical properties position it as a potential best-in-class therapy across multiple neuropsychiatric indications and symptom domains, with opportunities for once-daily oral dosing and a long-acting injectable formulation.
“Syremis was founded with a shared vision to advance mental health care through innovation grounded in emerging scientific and clinical insights”, said Elisabeth Kogan, Co-Founder and CEO of Syremis Therapeutics. “We are excited to announce the Series A financing to rapidly advance our pipeline into clinical proof of concept.”
“Schizophrenia and Alzheimer’s disease psychosis remain two of the most challenging of all neuropsychiatric disorders, and the need for new and effective therapies could not be greater,” said Steve Paul, MD, Syremis’ co-founder and member of the Board of Directors, and former CEO and Chair of Karuna Therapeutics. “With its balanced M1/M4 profile and promising pharmaceutical properties, Syremis has the potential to build on important clinical progress and ultimately transform the treatment landscape for patients and their families.”
The company is also advancing ST-901, a novel NMDA antagonist currently in IND-enabling studies. ST-901 will be developed for major depressive disorder and bipolar depression, two conditions with significant unmet need and high societal impact. Both ST-905 and ST-901 were initially discovered and developed at Clexio Biosciences and subsequently spun-out to Syremis Therapeutics.
“We are proud to support Syremis in its mission to bring forward novel, clinically grounded approaches for serious mental illness,” said Ilan Oren, Co-CEO of Dexcel Pharma. “The combination of a seasoned leadership team, compelling science, and strategic focus positions the company to deliver meaningful impact for millions of patients worldwide.”
Syremis is led by a seasoned team with deep expertise in drug development, neuroscience and a proven track record of delivering innovation.
Leadership Team:
- Elisabeth Kogan, Co-Founder and CEO
- Elena Kagan, Co-Founder and Chief Development Officer
- Menashe Levy, Co-Founder and Chief Technology Officer
Board of Directors:
- Ilan Oren, Board Chair, Co-CEO, Dexcel Pharma
- Reid Huber, Partner, Third Rock Ventures
- Uri Oren, Co-CEO, Dexcel Pharma
- Steve Paul, Syremis Therapeutics co-founder; former CEO and Chair of Karuna Therapeutics and former EVP for Science and Technology at Eli Lilly
- Ray Sanchez, Senior Advisor at Bain Capital Life Sciences, former CMO of Cerevel
- Elisabeth Kogan, Co-Founder and CEO of Syremis Therapeutics
“Syremis embodies the values we prioritize in our company-building efforts,” said Reid Huber, Partner at Third Rock Ventures. “With a highly capable team and compelling scientific foundation, the company is well-equipped to drive its programs forward with urgency and conviction.”
Leerink Partners acted as exclusive financial advisor for Syremis Therapeutics' Series A financing.
About Syremis Therapeutics
Syremis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health disorders. The company’s neuropsychiatric pipeline is rooted in emerging and clinically validated mechanisms of action, including muscarinic M1/M4 agonism and next-generation NMDA antagonism. Syremis’ lead program, ST-905, is a dual M1/M4 agonist in Phase 1 development for schizophrenia and other psychiatric conditions. Please visit www.syremis.com to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251218743253/en/
Contacts
Media
Corey O’Keeffe
corey@thirdrockventures.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Announces Results of the Annual General Meeting2.4.2026 16:49:00 CEST | Press Release
SES (the “Company”) held the Annual General Meeting (“AGM”) of Shareholders today in Betzdorf, Luxembourg. Following the recommendations made by the Board of Directors of SES, the shareholders have voted in favor of all resolutions, including the Company’s 2025 annual accounts and the proposed annual dividend of EUR 0.50 per A-share (EUR 0.20 per B-share). The total dividend amount comprises the interim dividend of EUR 0.25 per A-share (EUR 0.10 per B-share), which has already been paid to shareholders on October 16, 2025. The final dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) will be paid to shareholders on April 16, 2026. “I would like to sincerely thank our shareholders for their active engagement, visionary support and continued confidence in SES’ strategy,” said Adel Al-Saleh, CEO of SES. “The outcomes of today’s AGM underscore our shared commitment to a bold multi-orbit approach, with Medium Earth Orbit as the strategic backbone of a dynamically evolving global interco
Forrester: Three Years Into GenAI, Enterprises Are Still Chasing Its True Transformative Value2.4.2026 16:00:00 CEST | Press Release
According to Forrester’s (Nasdaq: FORR) latest report, Accelerate Your AI Voyage, most enterprises are struggling to turn growing AI adoption and investment into measurable business impact. One of the key factors holding businesses back is low artificial intelligence quotient (AIQ) — Forrester’s measure of AI aptitude — with many employees lacking a clear understanding of how to use AI. Other barriers include an overemphasis on productivity-focused use cases, difficulty measuring impact, and siloed adoption within individual functions. While these challenges can leave firms frozen in doubt or indecision, the wait-and-see approach to AI adoption is no longer viable. To unlock AI’s full potential, organizations need to focus on four key areas: Define the business outcomes and success metrics for what they want AI to achieve; identify specific use cases for AI deployment aligned to those business outcomes; establish a structured runway to plan, test, and strategically time the deployment
Andersen Consulting Adds Multiplica2.4.2026 15:30:00 CEST | Press Release
Andersen Consulting enters into a Collaboration Agreement with Multiplica, a digital consulting firm that helps organizations design, build, and scale impactful digital experiences. Founded in Spain with a presence in Latin America and the U.S., Multiplica focuses on user research and discovery, customer experience research, digital strategy, data modeling and analysis, report automation and data visualization, conversion rate optimization, product design, and user experience design. The firm helps organizations accelerate digital transformation by building digital capabilities, teams, and assets that advance expertise across digital products, consulting, and talent development. Multiplica enables clients to forecast emerging trends in digital experience and transform their businesses through enhanced digital channels and customer engagement. “Collaborating with Andersen Consulting represents an exciting opportunity to extend our reach and impact,” said David Boronat, CEO of Multiplica
The LYCRA Company Announces Strategic Partnership on Renewable LYCRA ® Fiber2.4.2026 15:00:00 CEST | Press Release
The LYCRA Company, a global leader in innovative and sustainable fiber solutions for the apparel and personal care industries, today announced the signing of a strategic partnership agreement with Texhong International Group Limited (“Texhong”), one of the world’s largest suppliers of core-spun cotton textiles. Under the agreement, Texhong will exclusively partner with The LYCRA Company to bring Renewable LYCRA® fiber made with 30 percent plant-based content* to China’s core-spun yarn sector. This collaboration aims to accelerate the adoption of bio-derived spandex across the global apparel and textile industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260402505834/en/ The LYCRA Company announced a strategic partnership with Texhong International Group for renewable LYCRA® fiber. Pictured at the signing ceremony held in Shanghai (left to right): Jason Wang, Vice President, Asia, The LYCRA Company, and Zhou Xia, Chief O
Brightfin Unifies Brand Following Proven Optics Merger, Delivering a New Standard for Technology Cost Optimization2.4.2026 15:00:00 CEST | Press Release
Brightfin today announced that, following its merger with Proven Optics, the combined company will operate under a single brand: Brightfin. The unified company brings together deep expertise in Technology Expense Management (TEM) and IT Financial Management (ITFM) to help organizations better understand, manage, and reduce total technology spend. Technology spending will exceed $6 Trillion this year, and for most organizations, it remains one of the least understood. CIOs can tell you what they’re spending. Far fewer can tell you whether it’s working. “Over the past several months, we’ve brought these two businesses together around a shared purpose: help enterprise businesses better understand and optimize their technology spend,” said Joel Martins, CEO of Brightfin. “What we are seeing now is a shift. Visibility alone isn’t enough. Teams need to be able to act, tied to real financial outcomes. See Clearly. Spend Better. That is our north star, and that is what our platform is built to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom